12:00 AM
 | 
Jul 23, 2012
 |  BioCentury  |  Finance

Crash diet

Vivus stock drops after Citron Research questions IP for obesity drug Qsymia

Despite a 10% pop following last Tuesday's FDA approval of obesity drug Qsymia, Vivus Inc. ended the week off $3.02 (11%) at $24.15 - the stock's lowest close since mid-May.

The downward pressure came from a report issued by Citron Research that raised IP concerns related to Vivus' fixed-dose combination of phentermine and topiramate.

Citron describes itself as an online stock commentary website and has a disclaimer saying, "At any times the principals of Citron might hold a position in any of the securities profiled on the site." It's unclear whether Citron is short on Vivus, as short positions do not...

Read the full 491 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >